SEC Form SC 13G/A filed by agilon health inc. (Amendment)

2/12/24 10:26:08 AM ET

Misc Health and Biotechnology Services

Health Care

Get the next $AGL alert in real time by email

SC 13G/A 1 AgilonHealthAGL.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3)* agilon health, inc. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 00857U107 ----------------------------------------------------- (CUSIP Number) December 31, 2023 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.00857U107 13G Page 2 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 40,453,329 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 43,816,286 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 43,816,286 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 10.8% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.00857U107 13G Page 3 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley Investment Management Inc. I.R.S. # 13-3040307 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 40,218,567 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 43,571,424 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 43,571,424 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 10.7% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: IA, CO -------------------------------------------------------------------------------- CUSIP No.00857U107 13G Page 4 of 8 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: agilon health, inc. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 6210 E HWY 290 SUITE 450 AUSTIN TX 78723 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley (2) Morgan Stanley Investment Management Inc. -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway New York, NY 10036 (2) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. (2) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 00857U107 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.00857U107 13G Page 5 of 8 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of December 31, 2023.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit 99.2 Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.00857U107 13G Page 6 of 8 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 12, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY Date: February 12, 2024 Signature: /s/ Deidre A. Downes -------------------------------------------------------------------- Name/Title: Deidre A. Downes/Authorized Signatory, Morgan Stanley Investment Management Inc. -------------------------------------------------------------------- Morgan Stanley Investment Management Inc. EXHIBIT NO. EXHIBITS PAGE ----------- ---------- ---- 99.1 Joint Filing Agreement 7 99.2 Item 7 Information 8 * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.00857U107 13G Page 7 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT --------------------------------------------------- February 12, 2024 --------------------------------------------------- MORGAN STANLEY and Morgan Stanley Investment Management Inc. hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley Morgan Stanley Investment Management Inc. BY: /s/ Deidre A. Downes --------------------------------------------------------------------- Deidre A. Downes/Authorized Signatory, Morgan Stanley Investment Management Inc. * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.00857U107 13G Page 8 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.2 ------------------ ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley.

Get the next $AGL alert in real time by email

Date	Price Target	Rating	Analyst
11/11/2024		Mkt Outperform → Mkt Perform	JMP Securities
11/8/2024		Outperform → Mkt Perform	William Blair
10/30/2024	$7.00 → $2.50	Neutral → Sell	Citigroup
10/2/2024	$3.00	Buy → Underperform	BofA Securities
5/30/2024	$6.00	Neutral	Robert W. Baird
4/22/2024	$6.00	Neutral	Citigroup
3/6/2024	$5.00	Underweight	Barclays
2/26/2024	$25.00 → $6.50	Buy → Hold	Jefferies

SEC Form SC 13G/A filed by agilon health inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $AGL

$AGL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO & President Sell Steven bought $67,188 worth of shares (20,000 units at $3.36) (SEC Form 4)

Kornitzer Benjamin bought 5,434 shares and covered exercise/tax liability with 1,883 shares, increasing direct ownership by 6% to 62,058 units (SEC Form 4)

Venkatachaliah Girish covered exercise/tax liability with 1,883 shares and bought 5,434 shares, increasing direct ownership by 10% to 39,950 units (SEC Form 4)

$AGL SEC Filings

agilon health inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by agilon health inc.

agilon health inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$AGL Market Insights

Live Market Insights

Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Beyond The Numbers: 6 Analysts Discuss Agilon Health Stock

Evercore ISI Group Maintains In-Line on Agilon Health, Raises Price Target to $7

$AGL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Agilon Health downgraded by JMP Securities

Agilon Health downgraded by William Blair

Agilon Health downgraded by Citigroup with a new price target

$AGL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by agilon health inc.

Amendment: SEC Form SC 13G/A filed by agilon health inc.

Amendment: SEC Form SC 13G/A filed by agilon health inc.

$AGL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO & President Sell Steven bought $67,188 worth of shares (20,000 units at $3.36) (SEC Form 4)

Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 405 shares, decreasing direct ownership by 0.69% to 57,947 units (SEC Form 4)

Chief Financial Officer Schwaneke Jeffrey A. was granted 659,880 shares, increasing direct ownership by 1,030% to 723,930 units (SEC Form 4)

$AGL Press Releases

Fastest customizable press release news feed in the world

$AGL Financials

Live finance-specific insights

$AGL Leadership Updates

Live Leadership Updates

agilon health Reports Third Quarter 2024 Results

agilon health Sets Date to Report Third Quarter 2024 Financial Results

agilon health Reports Second Quarter 2024 Results

agilon health Reports Third Quarter 2024 Results

agilon health Sets Date to Report Third Quarter 2024 Financial Results

agilon health Reports Second Quarter 2024 Results

agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

agilon health Names Jeff Schwaneke New Chief Financial Officer

agilon health, inc. investors: Please contact the Portnoy Law Firm to recover your losses; May 28, 2024 deadline

Recent Analyst Ratings for
$AGL

$AGL
Insider Purchases

$AGL
SEC Filings

$AGL
Market Insights

$AGL
Analyst Ratings

$AGL
Large Ownership Changes

$AGL
Insider Trading

$AGL
Press Releases

$AGL
Financials

$AGL
Leadership Updates